Trial Profile
Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy(R)) in Anti-CTLA-4 Treatment-Naive Subjects With Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 14 Sep 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma; Uveal melanoma
- Focus Adverse reactions; Expanded access
- Acronyms CheckMate218
- Sponsors Bristol-Myers Squibb
- 06 Jun 2017 Results (n = 732) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Feb 2017 Status changed from recruiting to completed.
- 31 Dec 2016 Results of a retrospective analysis of 3 studies (CA209004, CA209069 and CA209218; n=119) published in the Journal of the National Cancer Institute